drug for ovarian cancer
Last Updated : GMT 06:49:16
Arab Today, arab today
Arab Today, arab today
Last Updated : GMT 06:49:16
Arab Today, arab today

By up to six months

Drug for ovarian cancer

Arab Today, arab today

Arab Today, arab today Drug for ovarian cancer

Drug can slow progress of ovarian cancer
London - Arabstoday

Drug can slow progress of ovarian cancer London - Arabstoday A drug can slow down the progress of ovarian cancer – known as the’ silent killer’ – by up to six months, claim researchers. A new trial of 1,500 women shows Avastin delays the advance of the disease by an average of two months, compared with standard chemotherapy. But women with the most aggressive disease got the biggest benefit, with the disease stalled for almost six months. Avastin, also known as bevacizumab, is already widely used in patients with colon cancer, and doctors believe it will become a standard treatment for ovarian cancer. Chief investigator Dr Tim Perren, Consultant Oncologist from St James’s Institute of Oncology, St James’s University Hospital, Leeds and Honorary Senior Lecturer at the University of Leeds, said: ‘These results are potentially very encouraging particularly for women with advanced ovarian cancer. ‘Bevacizumab is the first new drug for 15 years to show an advantage over existing treatments for women with this disease. ‘These results are however preliminary and will not be fully confirmed until early 2013.’ Ovarian cancer, which affects almost 7,000 women a year, is dubbed the ‘silent killer’ because symptoms are often diagnosed too late. About 4,400 women die each year from the disease, which claims the lives of over 85 per cent of patients if found at a late stage when it has spread to other parts of the body. There has been little improvement in overall survival rates since the introduction of the chemotherapy drug paclitaxel 15 years ago. Latest findings from an international trial sponsored by the UK Medical Research Council are published in The New England Journal of Medicine. The trial followed 1.528 ovarian cancer patients who were randomly allocated to receive either standard chemotherapy, or a combination of standard treatment and Avastin, following surgery to remove their tumour. The researchers recorded the time taken for the disease to return, measured by CT scan. The interim results of the trial, reported after 28 months of follow-up, show an overall slowing down of disease progression by around two months. The results suggest it may improve overall survival in women, and the biggest effect on delaying the disease was found in women with an aggressive form of the disease – by almost six months. Professor Max Parmar, director of the MRC Clinical Trials Unit and co-author of the study, said ‘This suggests that bevacizumab could be considered as a treatment for women with an advanced form of the disease, or whose cancer has come back after chemotherapy treatment. ‘However, the decision on whether to include the drug routinely should be delayed until we have further evidence on its impact on overall survival.’ Avastin is a ‘targeted’ cancer therapy that works by blocking the development of new blood vessels and interfering with the tumour’s ability to grow and spread to other parts of the body. Combining the drug with chemotherapy has been shown to improve the effectiveness of treatment in several other forms of the disease including lung, kidney and colorectal cancers, although it has proved to be less effective than hoped in breast cancer. Annwen Jones, chief executive of Target Ovarian Cancer, said ‘It is very exciting and positive news for women living with ovarian cancer in the UK. It is the first glimmer of hope that there are significant advancements in treatments for ovarian cancer on the horizon at last. ‘We said previously the real challenge was to find well-tolerated treatments that prolong the lives of women, and it seems that Avastin is now a significant step nearer to realising that goal.’ Roche, which manufactures the drug, has applied to the European Medicines Agency for a licence to use it to treat ovarian cancer and a decision is expected shortly. It will need to be approved by the NHS rationing body, Nice, before it is widely used but in the meantime cancer specialists can apply for funding on behalf of patients to the Cancer Drugs Fund in England.  

arabstoday
arabstoday

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

drug for ovarian cancer drug for ovarian cancer

 



Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

drug for ovarian cancer drug for ovarian cancer

 



GMT 09:37 2012 Saturday ,28 April

Asamoah Gyan celebrates UAE title

GMT 06:57 2017 Tuesday ,12 December

Latest Grateful Dead resurrection -- a duo

GMT 14:03 2017 Friday ,10 February

3 Chinese miners killed in accident in Albania

GMT 10:06 2018 Sunday ,14 January

Qanso, Kijian tackle recent developments

GMT 18:58 2017 Saturday ,04 March

Gold prices continue to fall

GMT 12:49 2017 Thursday ,24 August

Fadl Shaker could be arrested soon

GMT 02:06 2017 Monday ,30 October

May22/Jun21

GMT 22:28 2017 Thursday ,24 August

February20th-March20th

GMT 08:07 2017 Saturday ,18 November

BBA President visits BHA

GMT 02:27 2017 Saturday ,28 October

September24th-October23rd

GMT 14:20 2017 Saturday ,26 August

Former VW engineer gets 40 months
Arab Today, arab today
 
 Arab Today Facebook,arab today facebook  Arab Today Twitter,arab today twitter Arab Today Rss,arab today rss  Arab Today Youtube,arab today youtube  Arab Today Youtube,arab today youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©

arabstoday arabstoday arabstoday arabstoday
arabstoday arabstoday arabstoday
arabstoday
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
arabstoday, Arabstoday, Arabstoday